Table 3.
Comparison of patient-reported outcomes between the groups according to clinical disease activity level
| Remission/low disease activitya | Moderate-to-high disease activitya | |||||
|---|---|---|---|---|---|---|
| Measure | Concordant group (n = 10) |
Discordant group (n = 28) |
P value | Concordant group (n = 10) |
Discordant group (n = 18) |
P value |
| Pain VAS | 18.5 (3.0–26.0) |
37.0 (24.0–56.0) |
.006 | 36.0 (14.0–50.0) |
66.0 (56.0–74.0) |
.02 |
| HAQ-II | 0.2 (0.0–0.3) |
0.9 (0.5–1.2) |
.001 | 0.9 (0.4–1.2) |
1.2 (0.7–1.2) |
.10 |
| SF-MPQ-2 | 0.7 (0.3–1.6) |
1.4 (0.8–2.6) |
.10 | 1.9 (1.0–2.7) |
2.3 (1.8–3.9) |
.18 |
| WPI | 5.0 (1.0–8.0) |
6.0 (4.0–9.0) |
.18 | 4.0 (3.0–7.0) |
8.0 (6.0–10.0) |
.005 |
| SS score | 2.5 (1.0–4.0) |
4.0 (3.0–6.0) |
.11 | 4.0 (2.0–6.0) |
6.0 (3.0–8.0) |
.16 |
| PSD | 8.0 (2.0–12.0) |
9.0 (8.0–15.0) |
.13 | 7.5 (6.0–13.0) |
13.5 (10.0–16.0) |
.01 |
| BRAF score | 4.5 (3.7–5.3) |
5.2 (4.3–6.3) |
.23 | 5.0 (4.0–6.0) |
6.3 (4.3–7.0) |
.28 |
| PROMIS | ||||||
| Pain interference | 1.3 (1.1–1.8) |
1.9 (1.5–2.4) |
.05 | 2.2 (1.6–2.8) |
2.9 (2.1–3.5) |
.05 |
| Ability to participate | 4.3 (3.8–5.0) |
3.5 (3.1–4.2) |
.02 | 3.7 (3.1–4.0) |
3.3 (2.6–4.0) |
.43 |
| Sleep disturbance | 1.6 (1.3–2.3) |
2.1 (1.8–2.9) |
.06 | 2.3 (1.9–2.8) |
2.5 (1.8–3.3) |
.50 |
| Fatigue | 1.8 (1.0–3.4) |
2.6 (2.0–3.5) |
.10 | 2.9 (2.3–3.4) |
3.1 (2.3–3.8) |
.43 |
| MAAS | 5.0 (4.5–5.6) |
5.1 (4.6–5.4) |
.95 | 4.4 (4.1–4.9) |
5.3 (4.5–5.5) |
.07 |
| PHQ-9 | 1.0 (0.0–5.0) |
4.0 (2.0–6.0) |
.04 | 4.0 (2.0–11.0) |
4.0 (3.0–6.0) |
>.99 |
| GAD-7 | 0.0 (0.0–1.0) |
1.0 (0.0–3.0) |
.06 | 1.5 (0.0–4.0) |
1.5 (1.0–6.0) |
.71 |
Values are presented as median (interquartile range)
aDisease activity level was classified according to the Clinical Disease Activity Index
BRAF Bristol Rheumatoid Arthritis Fatigue, FRS Fibromyalgia Research Survey, GAD-7 Generalized Anxiety Disorder 7, HAQ-II Health Assessment Questionnaire II, MAAS Mindful Attention Awareness Scale, PHQ-9 Patient Health Questionnaire 9, PROMIS Patient-Reported Outcomes Measurement Information System, PSD polysymptomatic distress, SF-MPQ-2 Short-Form McGill Pain Questionnaire 2, SS Symptom Severity, VAS visual analog score, WPI Widespread Pain Index